The PSC Support Expert Panel provides insight, scientific direction, and expertise to PSC Support.
The members of the Expert Panel are either i) recognised authorities from leading academic and medical institutions on the clinical management and/or research of PSC or ii) people affected by PSC. Each devotes their time and expertise to improving the lives of people with PSC and gives their time freely to the PSC Support Expert Panel activities.
PSC Support Expert Panel Members
Professor David Adams
Professor Adams' clinical interests are transplant hepatology and autoimmune liver disease including PSC. Laboratory research interests are focused on mechanisms of immune-mediated liver disease.David Adams Professor of Hepatology, Director of the NIHR Biomedical Research Unit for Liver disease at the Queen Elizabeth Hospital, Pro-Vice-Chancellor, Head of College of Medical and Dental Sciences and Dean of Medicine and Director of NIHR Birmingham Biomedical Research Centre at the Queen Elizabeth Hospital, Birmingham.
Professor Adams is also a Trustee of PSC Support.
Professor Graeme Alexander
Graeme Alexander graduated from Bristol University Medical School in 1976. He started working in 1981 with Professors Roger Williams and Adrian Eddleston as a research fellow in the Liver Unit at King’s College Hospital, where he spent 10 years in all, eventually as Senior Lecturer. He was appointed University Lecturer in Hepatology and Medicine at Cambridge University in 1991, a joint appointment as Consultant Hepatologist with Addenbrooke’s Hospital to establish the hepatology service and provide support for the surgical liver transplant team led by Professor Sir Roy Calne. He was director of Liver services between 1991 and 2007 and director of specialist gastroenterology training between 2000 & 2005. The Cambridge Hepatobiliary Unit provided an introduction to hepatology for a large number of consultants appointed throughout the UK. He was a founding member of HCV Research UK, UK-PBC, PSC-UK, AIH-UK & HCC-UK and remains active in each. He has a basic research interest in liver senescence in its’ many manifestations. He has published over 300 original peer reviewed papers and a large number of other articles. In 2105 he moved to his current appointment as UCL Professor in the UCL Institute for Liver and Digestive Health in conjunction with the Royal Free Trust and was the President of the British Association for the Study of the Liver between September 2015 & September 2017.
Dr Richard Aspinall
Dr Richard Aspinall is a consultant hepatologist at the Queen Alexandra Hospital in Portsmouth.
He qualified as a doctor in 1992 and trained in hospital medicine, gastroenterology and hepatology in Liverpool, Sheffield, Cambridge and London. He was a Lecturer at the Royal Postgraduate Medical School, Hammersmith Hospital and was awarded a research PhD in Immunology from Imperial College, London. In 2004 he moved to California, where he was Associate Hepatologist at the Scripps Liver Center in San Diego for two years. On his return to the UK, he was a consultant at the University Hospital of Wales in Cardiff before relocating to Portsmouth in 2010, with the remit of establishing clinical services for people with liver conditions. The Portsmouth Liver Centre has since grown into one of the largest in Southern England, providing a range of specialist services including a satellite transplantation clinic with the Royal Free Hospital London.
He has a keen interest in evaluating new treatments for liver disorders and is the National Industry Lead for the NIHR Hepatology Research Network, as well as the Wessex regional lead for Hepatology. He is a member of national steering committees for the Improving Quality in Liver Services (IQILS) programme and the BASL Immune-Mediated Liver Disease special interest group. He is a regular contributor to the Lancet Commission into Liver Disease in the UK. From 2016-2019, he was the Liver Section secretary for the British Society of Gastroenterology.
Dr Luke Boulter
Luke Boulter graduated from the University of York in 2007 with a BSc(Hons) in Molecular Cell Biology. From there he went to work on the mechanisms of liver repair at the MRC Centre for Inflammation Research in Edinburgh, where he was awarded a PhD in 2011. After a short spell as a post-doctoral fellow in the MRC Centre for Regenerative Medicine, investigating the signals that promote the growth of cholangiocarcinoma, he started his own lab at the MRC Human Genetics Unit and works on the mechanisms by which the bile duct develops in the embryo, repairs itself during disease and becomes cancerous.
Luke is particularly interested in the fundamental biology of the bile duct in health and disease, with the ultimate goal of developing new therapies which can be developed to help patients.
Dr Roger Chapman
Dr Roger Chapman is a founding member (in 1992) of the International Autoimmune Hepatitis Group (IAHG) producing position papers in the field of Autoimmune Hepatitis. He was involved in the foundation of the International PSC Study Group (2009) facilitating collaboration between different international centres researching into PSC and the foundation of British Autoimmune Liver Disease study Group (2010). He is one of the authors of the current European (EASL) guidelines for “Cholestatic liver diseases” and the first author of the recent North American (AASLD) guidelines on the “Management of Primary Sclerosing Cholangitis”.
In 2014, Roger was awarded a Fellowship of the American Association for the Study of Liver Diseases (AASLD). In 2015, he was awarded the Lifetime Achievement Award from British Association of the Study of the Liver (BASL) and an Honorary Life Membership of BASL.
Roger is also a Trustee of PSC Support.
Dr Emma Culver
Dr Emma Culver is a clinician scientist in Oxford, with an interest in immune-mediated liver diseases including PSC, IgG4-related cholangitis and autoimmune hepatitis. She graduated from the University of Edinburgh with a BSc in Neuroscience (2001) and a Bachelor of Medicine and Surgery (2004), and from Oxford University with a DPhil in Clinical Medicine (2015).
She is the Chief Investigator for UK-IgG4, on the Steering Committee for the BASL Immune-Mediated Liver Disease Special Interest Group, and is a member of the international study groups for PSC and Autoimmune Hepatitis. She receives funding from the Wellcome Trust, Academy of Medical Sciences and NIHR BRC Oxford for translational research in immune-mediated liver diseases.
Dr Jessica Dyson
Dr Jess Dyson is a consultant hepatologist at the Freeman Hospital in Newcastle and an Honorary Clinical Senior Lecturer at Newcastle University.
She has a specialist interest in immune-mediated liver diseases including PSC, primary biliary cholangitis (PBC), autoimmune hepatitis (AIH) and overlap syndromes. She graduated from Newcastle University in 2005. She is the Principal Investigator for UK-AIH, on the Steering Committee for the BASL Immune-Mediated Liver Disease Special Interest Group, a member of the international study groups for PSC and AIH and a contributor to the Lancet Commission into Liver Disease in the UK.
She has just submitted her NIHR-funded PhD that focused on looking for potential environmental triggers for PSC, PBC and AIH.
Dr James Ferguson
Dr James Ferguson is the clinical lead for the IQILS project, Treasurer of BASL and was a co-author of the recent Lancet Commission on liver disease in the UK.
Dr Ferguson is a transplant hepatologist based at the Queen Elizabeth Hospital in Birmingham.
Dr Kate Lynch has spoken at various international meetings on her research as well as on PSC, and published over 20 manuscripts, review articles and book chapters in international peer-reviewed journals and textbooks. She is passionate about helping patients with PSC, in helping to manage their condition and teach them about their disease, as well as pursuing research which will improve outcomes for patients living with PSC. She is involved in patient and public education on the condition, speaking at various patient support group meetings as well as being an expert medical advisor to PSC Support UK and PSC Support Australia. She has recently returned to Adelaide, Australia, after 7 years at Oxford under the tutelage of Dr Roger Chapman and Prof Satish Keshav, and she aims to continue her research in this area in Australia.
Dr Kate Lynch (née Williamson) is a gastroenterologist and hepatologist practising in Adelaide, South Australia. Her interests lie in autoimmune liver diseases, such as PSC, PBC and autoimmune hepatitis, as well as inflammatory bowel disease. She has just recently completed her DPhil in Clinical Medicine at University of Oxford, entitled "Peripheral blood, Liver and Intestine-specific lymphocytes in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease".
Her current research involves analysis (via flow cytometry, immunohistochemistry and single cell RNA sequencing) of immune cells derived from the peripheral blood, gut, and liver in patients with PSC/IBD and controls. In particular, she harnesses a minimally invasive technique, fine needle aspiration of the liver, to access immune cells directly from the PSC liver. The aim of her research is to understand further the gut-liver axis role in the pathophysiology of PSC/IBD. In addition to laboratory-based research, Kate is involved in clinical trials of novel agents in both PSC and IBD.
Dr Simon Rushbrook
Dr Simon Rushbrook is a hepatologist with a sub-speciality in Hepatobiliary Medicine and Liver Transplantation
His clinical expertise is in the management of patients with acute and chronic liver disease (especially autoimmune liver disease and particularly PSC), liver transplantation and Hepatobiliary medicine. He provides endoscopic management of portal hypertension and performs ERCP (+spyglass cholangioscopy) and radial and linear endoscopic ultrasound (EUS).
In 2008, Simon established a UK consortium of investigators for the collection of DNA and clinical data from patients with primary sclerosing cholangitis (UK-PSC). This has led to a number of high impact publications in the area of PSC genomics alongside clinical scoring systems of PSC through international collaborations, one of which was recently published in Hepatology (UK-PSC Risk Score).
Simon qualified in 1997 from the United and Medical Dental Schools of Guys and St Thomas’s. Having completed his House jobs in London he moved to Cambridge where he completed a 4 year PhD establishing the role of T regulatory cells in chronic viral hepatitis. During this time he gained experience in liver transplantation and acute and chronic liver disease. Simon then undertook further period of training in the Cambridge liver unit pre-and post-CSST. During his PhD and training, he undertook ERCP and EUS and has continued to develop an interest in hepatobiliary disease/liver autoimmune disease (particularly PSC) through UK-PSC and his clinical practice. He is currently the service lead for the BASL committee and sits on the UK Cholangiocarcinoma Board and UK-PSC Steering group. Simon was clinical director for gastroenterology department at the Norfolk and Norwich University Hospitals and was responsible for the opening of the Quadram Institute endoscopy department and Clinical Research and Trials Unit.
Simon enjoys spending time with his family and playing both classical and jazz piano.
Dr Francesca Saffioti
Dr Francesca Saffioti is a Consultant Hepatologist at Oxford University Hospitals. She graduated in Medicine with First class honours in 2008, from the University of Messina, Italy, where she also obtained her CCT in Internal Medicine in 2014. She subsequently undertook specialist training in Hepatology at the Royal Free Hospital, London, where she developed particular interest in the study of the cholestatic and autoimmune liver diseases (primary sclerosing cholangitis, primary biliary cholangitis and autoimmune hepatitis), as well as in the non-invasive assessment of liver fibrosis and portal hypertension. She completed a PhD in Clinical and Surgical Biotechnologies at the University of Messina, Italy, in 2018, on the topic of “Non-invasive assessment of liver fibrosis and portal hypertension in primary sclerosing cholangitis and primary biliary cholangitis: transient elastography, point share wave elastography and biomarkers”, and additionally obtained the title of Doctor Europeus.
Francesca is an active member of the International Study Groups for PSC, the UCL Immune & Cholestatic Liver Disease group of the Institute for Liver and Digestive Health, London, the British (BASL), the Italian (AISF), the European (EASL) and the American (AASLD) associations for the Study of the Liver.
She has authored more than 20 papers published in international peer-reviewed journals, 3 chapters in medical textbooks, and has presented her scientific work in numerous national and international conferences.
Francesca has been a collaborator of PSC Support since 2014.
She remains actively involved in research, and has been sub-investigator in several clinical trials for the study of novel therapeutic options in PSC.
Dr Brijesh Srivastava
Dr Brijesh Srivastava is a consultant Hepatologist and clinical lead for Liver services at University Hospital of Wales, Cardiff. He is a member of the national liver disease implementation group in Wales. His sub-speciality interest is in cholestatic and autoimmune liver diseases.
Brijesh completed his specialist liver training at Addenbrooke’s Hospital, Cambridge and trained in ERCP. Brijesh was the UK-PSC research fellow from 2010 until 2013, during which time he recruited patients with PSC and collected their DNA samples for the UK-PSC study. He has presented his research work at various national and international meetings.
Dr Douglas Thorburn
His clinical and academic interests are autoimmune and cholestatic liver diseases, biliary endoscopy and liver transplantation with a particular interest in PSC. Dr Douglas Thorburn has been a consultant hepatologist since 2003, initially in Birmingham, and since 2007 at the Royal Free.
Doug has published regularly on PSC and is the Chair of UK-PSC. He is Clinical Director for liver services at the Royal Free and Chair of the NHSBT Liver Advisory Group.
Dr Palak Trivedi
Dr. Trivedi is a clinician scientist and consultant hepatologist in Birmingham, who leads the Birmingham PSC and PBC clinical research program.
He has current interest in immune-mediated liver disease and liver transplantation, and is the current Chief Investigator for UK-PSC and Chair of the BASL Immune-Mediated Liver Disease special interest group (SIG).
Dr Andrew Yeoman
Dr Andrew Yeoman qualified in 1998 from the University of Wales College of Medicine and subsequently trained in hepatology in Wales, Auckland and Kings College, London where he was awarded an MD for studying clinical outcome prediction in autoimmune hepatitis.
He was appointed as a Consultant Hepatologist at the Gwent Liver Unit in 2010 and, since 2015, has been clinical lead for the Wales Liver Disease Delivery Plan.
Dr Yeoman's clinical interests lie in autoimmune liver disease and the early detection of liver disease and its complications. He is a member of the Lancet Commission into Liver Disease in the UK and has served on the BSG Guidelines Development Groups for the Management of Abnormal Liver Blood Tests and Autoimmune Hepatitis. He is also a steering committee member of the BASL Immune-Mediated Liver Disease special interest group (SIG).
Maxine Tapp (née Cowlin)
Maxine was diagnosed with PSC in 2006 at the age of 17. After 7 years of her PSC staying fairly under control, studying dance at university, working and travelling, Maxine’s condition progressed unexpectedly and significantly. She was listed for transplant in 2013 and spent 15 months on the transplant waiting list until she received her new liver.
In December 2018, Maxine was appointed as Programme Development Officer for PSC Support, becoming the charity’s first ever employee.
'PSC Support has helped me enormously since my diagnosis in 2006. Without the charity and its commitment to supporting patients and providing up to date, quality information, my experience with PSC would have been even more challenging. I am extremely passionate about fulfilling the objectives of PSC Support and am dedicated to ensuring the charity continues to move forwards and help even more people.’
Chris a patient, who was diagnosed with PSC in 2013. He works at the University of Leeds, teaching and researching in Business, Human Resources and Employment Relations.
Chris' hobbies include running and playing the saxophone. He enjoys raising money for PSC Support through his running, most recently completing the Great North Run and Yorkshire Marathons.
He enjoys helping PSC Support in their important work in providing information, advocating for patients and funding vital research.
Diagnosed with PSC and an AIH overlap in 2008, Gary underwent a liver transplant in January 2017 after just 9 weeks on the waiting list.
Having experienced the condition from diagnosis through transplant, I wanted to share my experience of PSC with other patients to provide a level of transparency and reality; particularly in the younger age group and those with children.
The work that Martine and the wider PSC Support team continuously undertake has been invaluable in helping to improve the lives of people with primary sclerosing cholangitis (PSC) through support, education, advocacy and research.'
Gary is also a Trustee of PSC Support.
Martine, PSC Support Trustee, was diagnosed with PSC in 2007, and has volunteered for PSC Support since then, becoming Chair of Trustees in 2011. She is driven and committed to doing everything in her power to help progress PSC research towards effective treatment, and making those treatments accessible to all PSC patients.
Recognising that there was a gap between the way medical professionals saw PSC and the way PSC patients saw (and lived with) PSC, she drew together and evidenced patient perspectives through PSC Support to help drive improvements in care and to influence PSC research direction. This was the impetus for the PSC Quality of Life Measure, which is under development in the UK.